title: Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus.
abstract: The specificity and immunoglobulin isotype distribution of antiphospholipid (aPL) antibodies have been evaluated in 68 patients with systemic lupus erythematosus (SLE) by ELISA which employed a panel of 7 different PL antigens. A total of 49 patients (72%) were positive for aPL antibodies of different isotypes and directed to one or more PL epitopes. Prevalence of IgG anticardiolipin (aCL, 37%) was similar to that of the other negatively charged PLs phosphatidylserine (PS, 35%), phosphatidylinositol (PI, 35%), phosphatidylglycerol (PG, 35%) and phosphatidic acid (PA, 40%); prevalence reduced to 9-12% and 7-16% respectively for IgM and IgA isotypes to the same antigens. aPL antibodies to the zwitterionic PLs phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were also observed, though their prevalence was lower than that demonstrated for negatively charged PLs. Of the 36 SLE patients who were aCL negative (53%), 17 (25% of all patients and 47% of aCL-negative patients) were positive for aPL antibodies of different isotypes to one or more non-CL epitopes. During a mean follow-up period of 30 months, 10 patients had deep vein thrombosis (DVT) with a total of 21 events. By chi 2 test, a significant correlation was found between DVT and IgG aCL (p = 0.03) and between this event and the presence of lupus anticoagulant (LA) antibody (p = 0.04). However, stronger correlations were demonstrated between DVT and IgA aCL (p = 0.007), IgG anti-PS (p = 0.02), and IgA anti-PC, -PI and -PG (p = 0.02, 0.003 and 0.02, respectively), whereas no correlation was found between thrombotic events and aPL antibodies with PE and PA specificities.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Haematology and Blood Transfusion, Ospedale S. Carlo Borromeo, Milano, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Toschi
authors.forename: A
authors.initials: A
authors.lastname: Motta
authors.forename: C
authors.initials: C
authors.lastname: Castelli
authors.forename: S
authors.initials: S
authors.lastname: Gibelli
authors.forename: C
authors.initials: C
authors.lastname: Cimminiello
authors.forename: G L
authors.initials: GL
authors.lastname: Molaro
authors.forename: A
authors.initials: A
authors.lastname: Gibelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000032:analysis; D017152:Antibodies, Antiphospholipid / Q000032:analysis* / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000209:etiology / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000145:classification / Q000276:immunology*; D013924:Thrombophlebitis / Q000209:etiology / Q000276:immunology
chemical_list: D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D001324:Autoantigens; D007132:Immunoglobulin Isotypes; D010743:Phospholipids